Welcome to our dedicated page for CEL-SCI SEC filings (Ticker: CVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cel-Sci Corporation's SEC filings reveal the financial realities and clinical progress of a development-stage biotechnology company. For investors evaluating CVM stock, these documents provide essential information that press releases rarely detail.
The company's 10-K annual reports disclose cash runway calculations, a critical metric for pre-revenue biotechs. Understanding how many quarters of operating expenses Cel-Sci can cover with existing capital helps assess financing risk. These filings also detail research and development expenses, showing how much capital flows into clinical programs versus administrative overhead. Our AI summaries extract these key figures without requiring you to navigate complex accounting presentations.
10-Q quarterly reports track Cel-Sci's cash burn rate and any changes to clinical trial timelines. Development-stage biotechs often update trial enrollment status and regulatory milestone expectations in their quarterly filings. These details appear in management discussion sections that our platform highlights for quick review.
8-K filings from Cel-Sci announce material events including clinical trial results, FDA meeting outcomes, and partnership agreements. For a biotech focused on a single lead drug candidate, each 8-K potentially carries significant information about the company's core asset. Track these filings to stay informed about Multikine development progress and corporate strategy shifts.
Form 4 insider transactions show when executives and directors buy or sell CVM stock. In small biotechnology companies, insider trading patterns can provide signals about internal confidence, particularly around clinical milestones. Our platform tracks these transactions and presents them in accessible format.
Shelf registration statements (S-3) and prospectus supplements (424B5) document Cel-Sci's capital-raising activities. Following these filings helps investors anticipate dilution and understand the company's financing strategy.
Cel-Sci Corp (CVM) Form 4: Senior Vice President John Cipriano received 7,500 stock options on 07/28/25 at an exercise price of $8.20, expiring 07/27/35. Vesting occurs in three equal annual tranches beginning one year from grant. No common shares were bought or sold; the filing records an “A” code equity award rather than an open-market transaction. After the grant, Cipriano holds 38,008 derivative securities. The award is typical incentive compensation with negligible near-term cash flow or dilution impact for shareholders.
CEL-SCI Corp (CVM) – Form 4 insider transaction
Director Robert E. Watson bought 2,919 restricted shares of CEL-SCI on 25-Jul-2025 at $6.85 (prior day’s close), a cash outlay of roughly $20k. Following the purchase, Watson’s direct holdings increased to 3,733 shares. No derivative securities were involved and the filing shows the transaction was made directly with the company, suggesting an equity-based compensation or voluntary open-market style purchase rather than option exercise or planned sale. The filing does not reference any concurrent sales, options, or changes in indirect ownership.
The transaction is modest relative to CEL-SCI’s market capitalization and daily trading volume, but insider buying—especially by a board member—can signal personal confidence in the company’s prospects and may be viewed positively by investors monitoring governance alignment.
FAQ
What is the current stock price of CEL-SCI (CVM)?
What is the market cap of CEL-SCI (CVM)?
